KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer. Sheng H, Shi G, Lu Y, Zheng S, et al. Oncogene 2025 Sep 23. doi: 10.1038/s41388-025-03576.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sheng H, Shi G, Lu Y, Zheng S, et al. KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer. Oncogene 2025 Sep 23. doi: 10.1038/s41388-025-03576.
PMID: 40983636